Effect of Growth Hormone Replacement Therapy on Plasma Brain Natriuretic Peptide Concentration, Cardiac Morphology and Function in Adults with Growth Hormone Deficiency

Lazúrová, Ivica; Pura, Mikuláš; Wagnerova, H; Tajtáková, M; Sedláková, Miluše; Tomàs, Lluís; Payer, Juraj; Hruzikova, P.; Vaňuga, Peter; Podoba, J; Trejbalová, L; Popović, Vera; Kołtowska-Häggström, Maria

doi:10.1055/s-0029-1220688

Cited by 11 publications

(9 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…High levels of NT-proBNP are observed in patients with severe GH deficiency and are corrected by GH therapy (13,34,35). However, in such conditions, the observed changes in these natriuretic peptides are not correlated with changes in cardiac structure or function (35,36,37), thus suggesting that effects of GH are here independent of cardiovascular alterations. Alternatively, indirect effects of GH through its effects on kidney filtration and fluid equilibrium may also be considered.…”

Section: Discussionmentioning

confidence: 99%

Active acromegaly is associated with decreased hs-CRP and NT-proBNP serum levels: insights from the Belgian registry of acromegaly

Verhelst

Velkeniers²,

Maiter

et al. 2013

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: Patients with active acromegaly have an increased prevalence of cardiomyopathy and heart failure but a less than expected risk of coronary artery disease, considering the frequent association of diabetes mellitus and hypertension. We examined whether changes in high-sensitive C-reactive protein (hs-CRP) and N-terminal pro-brain natriuretic peptide (NT-proBNP) might contribute to this phenomenon. Design and methods: Two hundred patients of the Belgian acromegaly registry (AcroBel) were divided in two groups: active disease (IGF1 Z-score O2; nZ95) and controlled disease (IGF1 Z-score %2; nZ105). Serum levels of hs-CRP and NT-proBNP were measured and correlated with BMI, blood pressure, fasting lipids, fasting glucose and insulin, HbA1c, IGF1, interleukin 6 (IL6), adiponectin, and sE-selectin. In a subset of acromegaly patients, hs-CRP, IL6, and NT-proBNP levels were also compared with those/the values of an age-, gender-, and BMI-matched reference group.

show abstract

Section: Discussionmentioning

confidence: 99%

Active acromegaly is associated with decreased hs-CRP and NT-proBNP serum levels: insights from the Belgian registry of acromegaly

Verhelst

Velkeniers²,

Maiter

et al. 2013

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Since 2003 additional studies have been published [20][21][22][23][24][25][26][27][28][29][30]. Although the GH replacement doses in these newer studies are lower and less variable, conflicting result have still been reported [25,26].…”

Section: Discussionmentioning

confidence: 99%

“…Two patients had isolated GHD whereas the rest had insufficiencies in at least one of the other pituitary axes: Adrenal axis (n = 10, mean hydrocortisone dose 20 mg/day, range [15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30], thyroid axis (n = 13, mean thyroxin dose 85 lg/day, range 50-150) and gonadal axis (n = 12, 5 females, 7 males). Two patients had been treated with GH during childhood for *3 years, and the treatment had been paused for 5 and 20 years before entering this study.…”

Section: Patientsmentioning

confidence: 99%

Cardiac function in growth hormone deficient patients before and after 1 year with replacement therapy: a magnetic resonance imaging study

et al. 2010

View full text Add to dashboard Cite

Assessed by conventional echocardiography the influence of growth hormone deficiency (GHD) and effects of replacement therapy on left ventricle (LV) function and mass (LVM) have shown inconsistent results. We aimed to evaluate cardiac function before and during replacement therapy employing the gold standard method cardiac magnetic resonance imaging (CMRI) and measurements of circulating levels of B-type natriuretic peptides. Sixteen patients (8 males and 8 females, mean age 49 years (range 18-75)) with severe GHD and 16 matched control subjects were included. CMRI was performed at baseline and after 1 year of GH replacement therapy. IGF-I, B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) were measured after 0, 1, 2, 3, 6 and 12 months of treatment. IGF-I Z-score increased from (median (IQR)) -2.3 (-3.8 to -1.4) to 0.5 (-0.3 to 1.7). LVM index (LVMI), ejection fraction (range 63-80%), cardiac output index and levels of BNP and NT-proBNP were similar at baseline in patients compared to controls (P-values from 0.09 to 0.37). The patients had significantly smaller LV end-diastolic volume index (P = 0.032) and end-systolic volume index (P = 0.038). No significant change in LV systolic function or LVM occurred during 1 year of GH treatment. BNP levels were unchanged (P = 0.88), whereas NT-proBNP tended to decrease (P = 0.052). Assessed by the highly sensitive and precise CMRI method, untreated GHD was not associated with impaired systolic function or reduced LVMI and 1 year of GH replacement using physiological doses did not influence cardiac mass or function.

show abstract

“…The height of children is rapidly becoming a social issue as there is an increase in the number of people who are concerned about their child's height. As a result, GH therapy is being indiscriminately used without adequate protection against side effects [38][39][40][41][42][43][44][45][46][47]. This study investigated the beneficial effect of using spirulina as a dietary supplement on skeletal growth and growth-related hormone levels in growing male rats.…”

Section: Introductionmentioning

confidence: 99%

Spirulina Enhances Bone Modeling in Growing Male Rats by Regulating Growth-Related Hormones

et al. 2020

View full text Add to dashboard Cite

In recent years, growth hormone deficiency in children has been treated with hormone therapy despite the possible significant side effects. Therefore, it was deemed beneficial to develop functional foods or dietary supplements for safely improving children’s growth. Spirulina platensis is known for its high antioxidant, anti-aging, anti-cancer, and immunity-enhancing properties, as well as its high digestibility and high protein content, but little has been reported about its influence on bone development in children with a normal supply of protein. In this study, we evaluated the effects of spirulina on the bone metabolism and antioxidant profiles of three-week-old growing male rats. The animals were divided into four groups (n = 17 per group) and were fed AIN93G diets with 0% (control), 30% (SP30), 50% (SP50), and 70% (SP70) of casein protein replaced by spirulina, respectively, for seven weeks. We observed that spirulina enhanced bone growth and bone strength by stimulating parathyroid hormone and growth hormone activities, as well its increased antioxidant activity. These results indicate that spirulina provides a suitable dietary supplement and alternative protein source with antioxidant benefits for growth improvement in early developmental stages.

show abstract

Effect of Growth Hormone Replacement Therapy on Plasma Brain Natriuretic Peptide Concentration, Cardiac Morphology and Function in Adults with Growth Hormone Deficiency

Abstract: Six months GH replacement therapy induced a significant decrease in plasma BNP levels despite the majority of patients having plasma BNP within the normal range at baseline. A borderline decrease in diastolic deceleration time was observed, the clinical significance of which is unclear.

Cited by 11 publications

References 21 publications

Active acromegaly is associated with decreased hs-CRP and NT-proBNP serum levels: insights from the Belgian registry of acromegaly

Active acromegaly is associated with decreased hs-CRP and NT-proBNP serum levels: insights from the Belgian registry of acromegaly

Cardiac function in growth hormone deficient patients before and after 1 year with replacement therapy: a magnetic resonance imaging study

Spirulina Enhances Bone Modeling in Growing Male Rats by Regulating Growth-Related Hormones

Contact Info

Product

Resources

About